Volume 75, Issue 1 pp. 42-50

Clinicopathologic features and treatment of postirradiation sarcoma of bone and soft tissue

Yoshiya Z. Inoue MD

Yoshiya Z. Inoue MD

Department of Orthopedics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

Search for more papers by this author
Frank J. Frassica MD

Frank J. Frassica MD

Department of Orthopedics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

Search for more papers by this author
Franklin H. Sim MD

Corresponding Author

Franklin H. Sim MD

Department of Orthopedics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

Mayo Clinic, 200 First Street SW, Rochester, MN 55905Search for more papers by this author
K. Krishnan Unni MB, BS

K. Krishnan Unni MB, BS

Division of Anatomic Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

Search for more papers by this author
Ivy A. Petersen MD

Ivy A. Petersen MD

Division of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

Search for more papers by this author
Richard A. McLeod MD

Richard A. McLeod MD

Department of Diagnostic Radiology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

Search for more papers by this author

Abstract

Background and Objectives

An analysis of the clinicopathologic features and treatment of patients with postirradiation sarcoma of bone and soft tissue was performed to guide modern evaluation and management.

Methods

A retrospective analysis of 135 sarcomas in 130 patients was performed.

Results

The mean age of the 130 patients was 48 years, and there was a female predominance because of irradiation for carcinomas of the breast and uterus. Indication for irradiation was a soft tissue lesion (such as lymphoma or breast cancer) in 58.5% of patients and a bone lesion (such as giant cell tumor or fibrous dysplasia) in 41.5%. The latent period (interval between irradiation and discovery of the sarcoma) ranged from 4–55 years (mean, 17 years). Of the lesions, 74% were stage IIB (high-grade extra-compartmental) and 24% were stage III (metastases). Ninety-four patients received their treatment at our institution. Of the 61 patients with resectable disease, 49 had amputations and 12 had limb salvage procedures. The 5-year cumulative survival rate was 68.2% for patients with peripheral (extremities, including proximal femur and hip) resectable lesions and 27.3% for patients with central (pelvis, head/neck, and ribs) resectable lesions. The local recurrence rate correlated with the surgical margin achieved: intralesional, 73%, marginal, 64%, and wide, 23%.

Conclusions

The prognosis for patients with peripheral resectable postirradiation sarcomas is good if a wide surgical margin can be achieved. This group of patients should be treated aggressively because they have a new cancer. J. Surg. Oncol. 2000;75:42–50. © 2000 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.